PMC8072118_01
The positron emission tomography-computed tomography (PET-CT) at baseline (before surgery). PET-CT showed masses in brain (arrow), thyroid and lung.
fonc-11-569429-g001.jpg
PMC8072118_01_fonc-11-569429-g001.jpg
f1
Figure 1 ). Further ultrasound revealed multiple thyroid nodules, the largest calcified one located in the left thyroid and measuring 41*30*44 mm. Supplementary Figure 1 ). The details of NGS were shown in the  Supplementary Data . These mutations combo are indicative of undifferential thyroid cancer, and rarely occur in lung cancers. Since the patient did not consent to further surgery, we did not obtain any operation samples on the thyroid or lung for further analysis.
Immunohistochemistry of the patient's brain cancer. From top to bottom, the immunochemistry results of the patient's brain tumor and negative control sample were shown. The patient's tumor showed positive of Napsin A (A), TTF-1 (B) and PAX8 (D), showing as "(+)" in top right corner of the graphs. Negative of TG (C) was identified, presenting as "(-)" in top right corner of the graphs. Corresponding negative results from negative control sample were also shown. Scale bar was in the lower right corner of each image. All images were magnified by 200 times. Scale bars (100mum) were provided.
fonc-11-569429-g002.jpg
PMC8072118_02_fonc-11-569429-g002.jpg
f2
TTF-1, TG and PAX8, negative of Napsin A ( Supplementary Figure 2 ). Targeted sequencing by using FSZ-Thyroid NGS Panel V1 (Genetronhealth) was performed on the tumor tissues of the three sons, the results of which showed all the tissues had BRAF V600E mutations ( Table 1  and  Supplementary Figure 3 ).
Computed tomography images (CT) of the thyroid and lung before and after anlotinib treatment. Arrows represent the masses. At base line, in addition to brain lesions, there were a mass in the left thyroid and some opaque mottled shadows and pulmonary nodules in the lung. Then the patient experienced brain surgery. Before anlotinib treatment, a huge mass in the left thyroid and two obvious pulmonary nodules was found. One month after anlotinib treatment, the pulmonary nodules were found to be controlled, thyroid tumor drastically reduced and tracheal compression relieved.
fonc-11-569429-g003.jpg
PMC8072118_02_fonc-11-569429-g003.jpg
f3
TTF-1, TG and PAX8, negative of Napsin A ( Supplementary Figure 2 ). Targeted sequencing by using FSZ-Thyroid NGS Panel V1 (Genetronhealth) was performed on the tumor tissues of the three sons, the results of which showed all the tissues had BRAF V600E mutations ( Table 1  and  Supplementary Figure 3 ).
PMC8072118_02
Immunohistochemistry of the patient's brain cancer. From top to bottom, the immunochemistry results of the patient's brain tumor and negative control sample were shown. The patient's tumor showed positive of Napsin A (A), TTF-1 (B) and PAX8 (D), showing as "(+)" in top right corner of the graphs. Negative of TG (C) was identified, presenting as "(-)" in top right corner of the graphs. Corresponding negative results from negative control sample were also shown. Scale bar was in the lower right corner of each image. All images were magnified by 200 times. Scale bars (100mum) were provided.
fonc-11-569429-g002.jpg
PMC8072118_02_fonc-11-569429-g002.jpg
f2
TTF-1, TG and PAX8, negative of Napsin A ( Supplementary Figure 2 ). Targeted sequencing by using FSZ-Thyroid NGS Panel V1 (Genetronhealth) was performed on the tumor tissues of the three sons, the results of which showed all the tissues had BRAF V600E mutations ( Table 1  and  Supplementary Figure 3 ).
Computed tomography images (CT) of the thyroid and lung before and after anlotinib treatment. Arrows represent the masses. At base line, in addition to brain lesions, there were a mass in the left thyroid and some opaque mottled shadows and pulmonary nodules in the lung. Then the patient experienced brain surgery. Before anlotinib treatment, a huge mass in the left thyroid and two obvious pulmonary nodules was found. One month after anlotinib treatment, the pulmonary nodules were found to be controlled, thyroid tumor drastically reduced and tracheal compression relieved.
fonc-11-569429-g003.jpg
PMC8072118_02_fonc-11-569429-g003.jpg
f3
TTF-1, TG and PAX8, negative of Napsin A ( Supplementary Figure 2 ). Targeted sequencing by using FSZ-Thyroid NGS Panel V1 (Genetronhealth) was performed on the tumor tissues of the three sons, the results of which showed all the tissues had BRAF V600E mutations ( Table 1  and  Supplementary Figure 3 ).